Gene therapy reduces HIV levels in small trials

September 20, 2011 by Deborah Braconnier report

(Medical Xpress) -- This weekend at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, Illinois, researchers from two different study groups, one on the east coast and one on the west coast, reported promising results from studies being conducted in gene therapy for the treatment of HIV.

In the last year, HIV patient Timothy Brown appeared to be cured from his HIV after receiving a from a patient who carried a mutated receptor known as CCR5 on the that the uses. These new studies are based on this case and the receptor CCR5.

The two studies included a total of 15 HIV-infected patients. The researcher removed T cells from the blood of the and modified them with an enzyme engineered by Sangamo BioSciences in California. This enzyme disables the CCR5 receptor. The patients were then infused with 10 billion modified cells.

The patients in the study were originally taking antiretroviral therapy when the study began. Within four weeks, six of the participants stopped taking their medication for a 12 week period. During this time, three of the patients saw a decrease in and one of the patient’s viral loads dropped to an undetectable level. This patient had an advantage at the beginning however. When it comes to genes, each person has two copies, one from the mother and one from the father. This patient already had one copied that carried a naturally occurring mutation. It is estimated that as many as five to 10 percent of HIV patients have a genetic form of this receptor already.

With an estimated 33 million people worldwide diagnosed with HIV, the hope of this research is to create what they call a “functional cure” for AIDS and reduce the need for antiretroviral therapy. More studies are needed to determine the level of gene modification that would provide a complete decrease in the HIV viral load. The goal is patients would still carry the virus but no longer need drugs to control it and prevent disease.

Related Stories

Recommended for you

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

Three-in-one antibody protects monkeys from HIV-like virus

September 20, 2017
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers ...

Fighting HIV on multiple fronts might lead to vaccine

September 20, 2017
A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.